BioSpace News Archive

Ascendis Pharma A/S (Nasdaq: ASND) today announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth hormone, somatropin) in adults with growth hormone deficiency (GHD).

Roche announced that healthcare professionals provided three of Roche’s navify digital solutions with excellent ratings, in terms of performance and satisfaction, in an independent report by KLAS® Research, a leading healthcare IT insights company.

Innate Pharma SA and Sanofi announced that Sanofi has exercised its option to license a natural killer cell engager program in solid tumors from Innate’s ANKET® platform pursuant to the terms of the research collaboration and license agreement signed in December 2022.

Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics has been granted NOK 16 million by the Research Council of Norway.

Medivir AB announced improved durable clinical benefit in maturing data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma, measured by local review.

Owkin announced that it has entered into a collaboration agreement with MSD, the trade name of Merck & Co Inc., Rahway NJ USA to develop and commercialize AI-powered digital pathology diagnostics for the EU market.

BioMed X announced a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application (BLA) for V116, the company’s investigational 21-valent pneumococcal conjugate vaccine specifically designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to beremagene geperpavec-svdt (B-VEC or VYJUVEK) for the treatment of dystrophic epidermolysis bullosa (DEB).

Kraig Biocraft Laboratories, Inc. announces that it has successfully completed the first pilot production test using a new two strain hybrid system.